Daxor Corporation has introduced its ezBVA Lab diagnostic service for outpatient blood volume analysis at a healthcare facility in eastern Kansas. This service offers clinicians precise, 98% accurate blood volume measurements within 24 hours without the need for capital equipment or lab infrastructure. By providing objective data on blood, plasma, and red cell volume, the service helps optimize patient treatment, reduce hospital readmissions, and lower healthcare costs. This expansion strengthens Daxor's presence in the Midwest and supports value-based care improvements.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Solana recorded 8.92 billion non-vote transactions from July to September 2026, marking a 104% increase compared to the fourth quarter of 2025. These transactions exclude validator votes and include activities like transfers, trading, and decentraliz...
Jio Platforms, backed by Meta and Google, has seen its IPO anchor book oversubscribed over 30 times, attracting $26.3 billion in bids for an $854 million portion. The company aims to raise up to $3.2 billion in India's largest-ever IPO by rupee value...
